Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Urate transport in health and disease
Victoria L. Halperin Kuhns, Owen M. Woodward
Best Practice & Research Clinical Rheumatology (2021) Vol. 35, Iss. 4, pp. 101717-101717
Open Access | Times Cited: 22

Showing 22 citing articles:

Hyperuricemia and its related diseases: mechanisms and advances in therapy
Lin Du, Zong Yao, H. Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 75
The Good, the Bad and the New about Uric Acid in Cancer
S. Allegrini, Mercedes Garcia‐Gil, Rossana Pesi, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4959-4959
Open Access | Times Cited: 42
Probiotics, bioactive compounds and dietary patterns for the effective management of hyperuricemia: a review
Lei Sun, Caixin Ni, Jianxin Zhao, et al.
Critical Reviews in Food Science and Nutrition (2022) Vol. 64, Iss. 7, pp. 2016-2031
Closed Access | Times Cited: 40
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Robert Terkeltaub
Drugs (2023) Vol. 83, Iss. 16, pp. 1501-1521
Closed Access | Times Cited: 32
Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases
Xin Wei, Mao Zhang, Shian Huang, et al.
The FASEB Journal (2023) Vol. 37, Iss. 7
Closed Access | Times Cited: 29
Structural Basis for Inhibition of Urate Reabsorption in URAT1
Junping Fan, Wenjun Xie, Han Ke, et al.
JACS Au (2025) Vol. 5, Iss. 3, pp. 1308-1319
Open Access | Times Cited: 1
Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1
Yongmei Li, Fengxin Zheng, Shiqi Zhong, et al.
European Journal of Pharmacology (2024) Vol. 971, pp. 176528-176528
Closed Access | Times Cited: 7
SLC2A9 rs16890979 reduces uric acid absorption by kidney organoids
Shouhai Wu, Chuang Li, Yizhen Li, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 11
Open Access | Times Cited: 5
Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment
Jing-wen Guo, Guo‐Qiang Lin, Xinyi Tang, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
Structural basis of disease mutation and substrate recognition by the human SLC2A9 transporter
Nitesh Khandelwal, Meghna Gupta, Paras Kumar, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 7
Open Access
Identification of pathogenic variants in the ABCG2 gene in patients with severe familial hyperuricemia and gout
Yu Toyoda, Kateřina Pavelcová, Jana Mašínová, et al.
Molecular and Cellular Biochemistry (2025)
Closed Access
Gout, Hyperuricemia and Psoriatic Arthritis: An Evolving Conundrum
Priyanka Chandratre, R. Sabido-Sauri, Sizheng Steven Zhao, et al.
Current Rheumatology Reports (2025) Vol. 27, Iss. 1
Closed Access
OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts
Yu Toyoda, Yusuke Kawamura, Akiyoshi Nakayama, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 18
Identification of a dysfunctional exon-skipping splice variant in GLUT9/SLC2A9 causal for renal hypouricemia type 2
Yu Toyoda, Sung Kweon Cho, Velibor Tasić, et al.
Frontiers in Genetics (2023) Vol. 13
Open Access | Times Cited: 7
Association of dietary inflammatory index with all-cause and cardiovascular disease mortality in hyperuricemia population: A cohort study from NHANES 2001 to 2010
Jingda Huang, Yandong Zhang, Jiajie Li, et al.
Medicine (2023) Vol. 102, Iss. 51, pp. e36300-e36300
Open Access | Times Cited: 6
Pathogenic Variants of SLC22A12 (URAT1) and SLC2A9 (GLUT9) in Spanish Patients with Renal Hypouricemia: Founder Effect of SLC2A9 Variant c.374C>T; p.(T125M)
Ana Perdomo-Ramírez, Elizabeth Córdoba-Lanús, Carmen Jane Trujillo-Frías, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8455-8455
Open Access | Times Cited: 5
SVCT2/SLC23A2 is a sodium-dependent urate transporter: functional properties and practical application
Yu Toyoda, Hiroshi Miyata, Ryuichiro Shigesawa, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 8, pp. 104976-104976
Open Access | Times Cited: 4
SGLT2 Inhibitors and Uric Acid Homeostasis
Ava M. Zapf, Owen M. Woodward
Gout Urate and Crystal Deposition Disease (2024) Vol. 2, Iss. 2, pp. 157-172
Open Access | Times Cited: 1
Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease
Gianmichele Massimo, Nicki Dyson, Fisayo A. Olotu, et al.
Antioxidants (2024) Vol. 13, Iss. 12, pp. 1439-1439
Open Access | Times Cited: 1
New SLC22A12 (URAT1) Variant Associated with Renal Hypouricemia Identified by Whole-Exome Sequencing Analysis and Bioinformatics Predictions
Ana Perdomo-Ramírez, Elena Ramos‐Trujillo, Félix Claveríe‐Martín
Genes (2023) Vol. 14, Iss. 9, pp. 1823-1823
Open Access | Times Cited: 3
Clerodendranthus spicatus [Orthosiphon aristatus (Blume) Miq.] maintains uric acid homeostasis via regulating gut microbiota and restrains renal inflammation in hyperuricemic nephropathy
Yang Wang, Kaiwen Li, Siya Yan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate
Isamu Matake, Tomoya Yasujima, Hirotaka Matsuo, et al.
Drug Metabolism and Pharmacokinetics (2024), pp. 101048-101048
Closed Access
Page 1

Scroll to top